Post-earnings recap
Reported
Wed, Feb 25, 2026
EPS actual
$0.68
EPS est.
$0.47
EPS surprise
+45.61%
1-day move
+2.77%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Catalyst Pharmaceuticals reported a strong earnings per share, significantly beating expectations, which contributed to a 2.77% increase in stock price. The positive EPS surprise indicates effective cost management and operational efficiency. However, the lack of revenue data and future guidance leaves some uncertainty for investors.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.68 | N/A | +45.61% |
| Revenue | N/A | N/A | N/A |
Management expressed satisfaction with the EPS results, highlighting strong operational performance. They emphasized their commitment to maintaining growth.
We are pleased with our performance this quarter, especially in EPS growth.
Our focus remains on sustaining our momentum in the upcoming quarters.